showed that dual anti-PD-1/VEGFR2 therapy has a durable vessel fortification effect on hepatocellular carcinoma (HCC) and can overcome treatment resistance to either treatment alone, and increase overall survival in HCC models by influencing the TME. The gene discussed is KDR; the disease is hepatocellular carcinoma.